[The femoral profunda artery within the scope of aneurysm disease].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Bessler.
Explore the source record for details and available documents.
The efficacy of naproxen sodium (naproxen-Na) in dysmenorrhea has been established in two independent double-blind (placebo-controlled) studies. An initial dose of 550 mg. of naproxen-Na was followed by 275 mg. every six hours for a maximum of five days. Twenty patients were included in Study I (10 treated with naproxen-Na) and 23 patients in Study II (12 treated with naproxen-Na). Each patient received the medication during four dysmenorrheic episodes. Thus, a total of 172 treatment courses could be evaluated. A variety of efficacy criteria were measured: frequency of pill intake, changes in pain intensity, the degree of relief achieved by the medication, and need for additional analgesics. In both studies naproxen-Na was demonstrated to be superior to the placebo treatment with high statistical significance in each of these parameters.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The short-term metabolic effects of cloprednol, a new short-acting synthetic corticosteroid, were evaluated in four normal subjects. Cloprednol, 12.5 mg/day, in one subject had no appreciable effect on urinary excretion of sodium, potassium, nitrogen, or calcium. Cloprednol, 20 mg/day, in three subjects had no significant effect on mean daily urinary sodium and potassium excretion, although mild, transient sodium retention and kaliuresis were observed. One subject had increased nitrogen excretion and all three had a small increase in calcium excretion. Prednisolone, 40 mg/day, a dose with antiinflammatory potency equivalent to 20 mg/day cloprednol, given subsequently to two subjects under identical conditions resulted in sodium and potassium excretion results similar to those of cloprednol, 20 mg/day, but produced a much greater increase in nitrogen and calcium excretion. These results suggest that, like prednisolone, cloprednol lacks the sodium-retaining properties of hydrocortisone and raise the possibility that cloprednol has less of a deleterious effect on nitrogen and calcium excretion than prednisolone.